United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer (PFE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to earnings of $1.78 per share a year ago.

Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates

Pfizer stock fell early Tuesday after the company reported bigger-than-expected losses and light sales for the third quarter.

Pfizer Skids As Covid Products Drive 41% Sales Decline, Losses

A smaller-than-expected third-quarter loss from Pfizer Inc (NYSE:PFE) was not enough to move the stock pre-market as it revealed the scars from a tail-off in demand from Covid treatments. Disclosing write-offs of $5.6 billion, $4.7 billion was attributed to its antiviral drug Paxlovid.

Pfizer Q3 earnings beat does little for the battered share price

Shares of Pfizer Inc. PFE, +1.46% edged up 0.1% in premarket trading Tuesday, after the drug maker reported that it swung to a wider-than-expected third-quarter loss and revenue fell more than forecast, amid weakness in COVID products, but still affirmed its full-year outlook. The company swung to a net loss of $2.38 billion, or 42 cents a share, from net income of $8.61 billion, or $1.51 a share, in the year-ago period.

Pfizer stock inches up after wider-than-expected loss, but full-year outlook kept intact

Pfizer on Tuesday reported its first quarterly loss since 2019, as the U.S. drugmaker recorded $5.6 billion in charges related to its COVID products like its antiviral treatment Paxlovid and vaccine Comirnaty.

Pfizer swings to quarterly loss due to Paxlovid write-off

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2023. The company reaffirms its 2023 revenue guidance(4) range of $58.0 to $61.0 billion and its outlook for Adjusted(3) diluted EPS of $1.45 to $1.65 provided on October 13, 2023. The third-quarter 2023 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer's R&D pipeline can be found at www.pfizer.com. EXECUTIVE COMMENTARY Dr. Al.

Pfizer Reports Third-Quarter 2023 Results

Disney

Lantheus Holdings

MercadoLibre

NextEra Energy

StoneCo

Atlassian

Risk and reward have an inverse relationship. It's one of the guiding principles of investing in stocks and any other asset.

7 Low-Risk Stock Picks to Double Your Money

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?

GlaxoSmithKline

Pfizer , which dominated COVID vaccine sales, now finds itself looking up at GSK , whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.

Pfizer RSV vaccine lags GSK's as head-to-head competition underway

American Express

Crown Hlds

Dollar General

Generac Holdings

Medtronic

Occidental Petroleum

As I type this, equity investors can relate to the statement “nowhere to run, nowhere to hide.” The tech-heavy NASDAQ index is down over 4% in the five days ending Oct. 26.

The 7 Most Undervalued Long-Term Stocks to Buy: October 2023

Eli Lilly

Roche Holding AG

Roche spent $7.1 billion on a company, primarily because of an IBD therapy. Pfizer just got approval for a pill to treat ulcerative colitis.

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Verizon

Walgreens

The stock market for the most part has had a solid year after a dreadful 2022, and those that owned any of the Magnificent 7 have had an incredible year.

These 3 Demolished ‘Strong Buy' Dividend Stocks Are the Cheapest in Over 7 Years

Albemarle

Chevron

Lockheed Martin

Altria

AT&T

Vale S.A.

Historically, the last quarter of the year has been good for equities. However, the markets seem to have started Q4 on a nervous note.

The 7 Most Undervalued Dividend Stocks to Buy: October 2023

Shares of Pfizer Inc (NYSE:PFE) and its German partner BioNTech rose after the two companies announced positive results from a Phase 1/2 study evaluating their combination vaccine candidates for COVID-19 and influenza. The company said its vaccine candidates, which were compared to a licensed influenza vaccine and their Omicron COVID vaccine, demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.

Pfizer's combination flu and COVID vaccine candidates effective, trial data shows

BioNTech SE

Pfizer and BioNTech said an early trial of a combined Covid-19 and influenza vaccine had produced positive data. The companies are set for a race with Moderna to release the first combination vaccine.

Pfizer Progresses Combo Covid Vaccine. It's Competing with Moderna.

Pfizer, Moderna and Novavax believe combination shots will simplify the process for people to protect themselves against Covid and the flu.

Pfizer's combination Covid, flu vaccine will move to final-stage trial after positive data

Johnson & Johnson

High-quality dividend stocks often deliver market-beating returns for shareholders. In 2023, though, a fair amount of these equities have struggled.

2 Magnificent Dividend Stocks That Could Deliver a Lifetime of Passive Income

Pfizer Inc. PFE and German partner BioNTEch SE BNTX announced positive results from a Phase 1/2 trial of their combined mRNA flu/COVID vaccine on Thursday in adults aged 18 to 64. The vaccine candidates were compared to a licensed influenza vaccine and the companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.

Pfizer and BioNTech announce positive data in early trial of flu/COVID combination vaccine

Pfizer and German partner BioNTech said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the virus strains in early- to mid-stage trials.

Pfizer, BioNtech say flu-COVID shot generates immune response

NEW YORK and MAINZ, GERMANY, October 26, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study ( NCT05596734 ) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit. The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.

Pfizer and BioNTech - Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' Omicron BA.4/BA.5-adapted bivalent COVID.

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Estee Lauder

Enphase Energy

KeyCorp

SPDR S&P Regional Banking ETF

LVMH Moet Hennessy Louis Vuitton

Moderna

PNC Financial Services

Polestar Automotive Holding UK PLC

SolarEdge Technologies

Teladoc

Tax-loss selling may occur earlier this year, instead of the during usual time of selling pressure in late December. DataTrek suggests a list of stocks that may bounce back in November that we discuss. FMC Corporation, SolarEdge Technologies, Moderna, KeyCorp, and The Estee Lauder Companies are stocks to avoid due to weak performance and market conditions.

5 Stocks To Sell Before Tax-Loss Season Begins

News for Pfizer Stock (PFE)